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Orexins/hypocretins exert cardiovascular effects which are centrally mediated. In the
present study, we tested whether orexins and their receptors may also act in an
autocrine/paracrine manner in the heart exerting direct effects. Quantitative reverse
transcription-PCR (RT-PCR), immunohistochemical and Western blot analyses revealed
that the rat heart expresses orexins and orexin receptors (OXR). In isolated rat cardiomy-
ocytes, only orexin-B (OR-B) caused an increase in contractile shortening, independent
of diastolic or systolic calcium levels. A specific orexin receptor-2 (OX2R) agonist ([Ala11,
D-Leu15]-Orexin B) exerted similar effects as OR-B, whereas a specific orexin receptor-1
(OX1R) antagonist (SB-408124) did not alter the responsiveness of OR-B. Treatment of the
same model with OR-B resulted in a dose-dependent increase in myosin light chain and
troponin-I (TnI) phosphorylation. Following ischaemia/reperfusion in the isolated Langen-
dorff perfused rat heart model, OR-B, but not OR-A, exerts a cardioprotective effect; mir-
rored in an in vivo model as well. Unlike OR-A, OR-B was also able to induce extracellular
signal-regulated kinase (ERK) 1/2 (ERK1/2) and Akt phosphorylation in rat myocardial tissue
and ERK1/2 phosphorylation in human heart samples. These findings were further corrobo-
rated in an in vivo rat model. In human subjects with heart failure, there is a significant neg-
ative correlation between the expression of OX2R and the severity of the disease clinical
symptoms, as assessed by the New York Heart Association (NYHA) functional classifica-
tion. Collectively, we provide evidence of a distinct orexin system in the heart that exerts a
cardioprotective role via an OR-B/OX2R pathway.
Introduction
Cardiovascular disease (CVD), including myocardial infarction, is the leading cause of morbidity and
mortality in theWesternworld [1,2].Orexins, also referred to as hypocretins, exist in two functional forms,
i.e. orexin A (OR-A) and orexin B (OR-B), which are derived from a common 130 amino acid precursor
peptide [3,4] and exert their actions by activating the orexin-1 (OX1R) and orexin-2 (OX2R) receptors.
OXRs belong to the G protein-coupled receptor (GPCR) superfamily [3] and are distributed throughout
both central and peripheral sites where they regulate endocrine, metabolic and cardiovascular functions
[5–7]. Of note, several established cardiovascular drugs exert their cardiac actions via GPCRs, such as the
muscarinic, angiotensin, adrenergic, and endothelin receptors [8].
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Growing evidence indicates that central orexin neurons are implicated in cardiovascular regulation [5]. For ex-
ample, in the central nervous system (CNS), both orexin and OX2R-containing nerve fibres have been identified in
the paraventricular nucleus (PVN) [9], an area which constitutes a vital central site for integration of sympathetic
outflow and cardiovascular function [10–17]. Thus, although orexins can influence the autonomic control of the
cardiovascular system, little is known about any direct effects of orexins in the heart.
We and others have provided evidence for a wide distribution of orexins and their receptors peripherally [18–20].
Wehave also demonstrated the presence ofOXRs in human adipose tissue, where theymodulate adipogenesis and adi-
pose tissue metabolism [7]. Herein, we hypothesised that orexins may also exert direct cardiac effects and we sought
to investigate the expression and function of cardiac OXRs using in vitro, ex vivo and in vivo models, corroborating
this with clinical data.
Materials and methods
Drugs and experimental solutions
Study treatment agents were: OR-A,OR-B (Phoenix Peptides), OX2R agonist ([Ala11, d-Leu15]-OR-B; Tocris), OX1R
antagonist (SB-408124; Tocris), wortmannin (PI3Kinase (PI3K) inhibitor; Sigma—Aldrich) and mitogen-activated
protein kinase (MAPK) inhibitor U0126 (Tocris). According to the manufacturer’s specifications on biological activ-
ity, the used OX2R agonist ([Ala11, d-Leu15]-OR-B; Tocris) is a ‘highly potent and selective OX2 receptor agonist;
displays 400-fold selectivity over OX1 receptors. EC50 values are 0.13 and 52 nM for human OX2 and OX1 recep-
tors respectively’. Similarly, the used OX1R antagonist (SB-408124) is a ‘selective non-peptide orexin OX1 receptor
antagonist (Kb values are 21.7 and 1405 nM for human OX1 and OX2 receptors respectively)’. Triphenyl-tetrazolium
chloride (TTC, Sigma–Aldrich) was used to determine the infarct size following ischaemia and reperfusion. All other
reagents used were of the highest purity commercially available.
Animal experiments
All animal experiments were performed in accordancewithU.K. legal requirements and the guidelines fromDirective
2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. This investigation
also conforms to the guidelines for the welfare of animals in experimental neoplasia as they have been developed
by the United Kingdom Coordinating Committee of Cancer Research (UKCCCR). Adult male Wistar rats (250–300
g) were housed in environmentally controlled conditions (22 +− 2◦C, humidity 40–60%) under a 12:12-h light–dark
schedule (lights on 06:00). After a week of habituation to these conditions, rats were killed using cervical dislocation.
Hearts were immediately removed for the following studies: (i) dissection and immediate snap-freezing for later tissue
analysis; (ii) isolation of ventricular cardiomyocytes by enzymatic digestion; (iii) immersion in ice-cold oxygenated
Tyrode’s solution and then perfusion via the aortic cannula in the modified Langendorff model with Tyrode’s solu-
tion at 37◦C, as previously described [21]. In brief, contractile parameters were measured by insertion of a fluid-filled
latex balloon through the left atrium (LA) into the left ventricle (LV), this was connected to a pressure transducer
(MTL0380, ADInstruments Ltd, U.K.) and the balloon volume was adjusted to give end-diastolic pressure of <10
mmHg. Aortic perfusion pressure was monitored with a second pressure transducer in series with the aortic cannula.
Data were continuously recorded using a Power Lab 8 preamplifier/digitiser (ADInstruments Ltd, U.K.). Hypotha-
lamic dissection took place as previously described [22]. All procedures were approved by the ethics committee and
complied with the University’s care and welfare guidelines, in strict accordance with the Home Office Guidance (PPL
70/7175) on Research and Testing using animals and the Animal (Scientific Procedures) Act, 1986 and the Guide for
the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No.
85-23, revised 1996).
Human cardiovascular multiple tissue cDNA panel
Commercially available human cardiovascular multiple tissue cDNA (MTC) panel (Clontech) were used for the
present study. All tissues were normal (i.e. non-diseased) and the amount of pooled patients varied from 11
up to 32. The sets of primers used for reverse transcription-PCR (RT-PCR) amplification were: (i) OX1R sense
5′-ccttcctggctgaagtgaag-3′ and antisense 5′-agtgggagaaggtgaagcag-3′ and (ii) OX2R sense 5′-gtcgcaactggtcatctgct-3′
and antisense 5′-cgtcctcatgtggtggttct-3′.
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Harvesting of single-cell mRNA and cDNA synthesis
Under the microscope, single rat cardiomyocytes (n=6) were harvested via the patch clamp micro-electrode pipette,
without losing the gigaseal to prevent contamination with extracellular fluid [23]. Subsequently, the pipette contents
were expelled into a sterile 0.5 ml tube.
PCR
Total RNA from different rat heart chambers (n=3) was extracted and cDNA synthesis was performed. PCRs were
carried out as previously described [7].
Immunoﬂuorescence for orexins and OXRs in cardiomyocytes
Adult rat cardiomyocytes, seeded on glass cover-slips were fixed with 4% paraformaldehyde in PBS. The primary
rabbit antiserum OR-A and OR-B (Phoenix Europe GmbH, Karlsruhe, Germany) and the primary goat polyclonal
OX1R (Santa Cruz Biotechnology Inc., U.S.A.) and a monoclonal OX2R antibody (Abcam, U.K.) were used at a 1:500
dilution. All dilutions were made in 3% BSA in PBS-0.01% Triton X-100. Specimens were incubated with primary
antibody for 60min, thenwashed three timeswith PBS (5min each time) before incubationwith anti-rabbit IgG-FITC
and Texas Red anti-goat secondary antibody (Vector Laboratories, Peterborough, U.K.) for 45 min. The slides were
then thoroughly rinsed with PBS, and the cell nuclei were visualised by applying the DNA-specific dye DAPI at a final
concentration of 1.5 μg/ml.
Immunohistochemistry for orexin and OXRs in the rat heart
Whole heart tissue sections from adult rats (n=3) were cut at 3 μm. Endogenous peroxidase was blocked by incubat-
ing sections in a 1.5%H2O2 solution for 20 min. The detection system used was an immunoperoxidase-based system
(Vector Universal Elite ABC kit) with a diaminobenzidine tetrahydrachloride visualisation agent. Sections were in-
cubated with primary antibody (OX1R, OX2R, OR-A and OR-B) for 60 min at room temperature. Sections were then
washed for 2 × 5 min in buffer. Secondary biotinylated antibody was applied for 30 min at room temperature. The
avidin–biotin complex solution was then applied to the sections and incubated for 30 min at room temperature (Vec-
tor Elite ABC reagent). DAB solution was prepared according to the manufacturer’s instructions and applied to the
sections for 5 min. Sections were then dehydrated, cleared and mounted.
For controls, rat spleen, testes (positive controls) and thymus (negative control) were stained using
paraffin-embedded tissues from US Biomax (#RA162, MD, U.S.A.). Furthermore, we have repeated the OR-A stain-
ing on rat heart array (#TR031; US Biomax MD, U.S.A.).
Western blotting for prepro-orexin and orexins
Protein lysates from rat brain, rat heart and human myometrium were separated using SDS/PAGE (15% polyacry-
lamide) under reducing conditions and then transferred on to immunoblot nitrocellulose membrane. Blocking of
non-specific binding was achieved by placing the membrane in a blocking buffer (1% BSA in 1× TBST) at 4◦C
overnight. The following day, membrane was rinsed with TBST for 5–10 min. Membranes were then incubated
with primary anti-rabbit OR-A and OR-B antibodies (Phoenix Peptides), diluted 1:500 and further incubated at 4◦C
overnight under gentle agitation. The next day, after rinsing the membrane three times in TBST for 10 min to remove
unbound primary antibodies, the membranes were exposed to anti-rabbit IgG–HRP conjugate (Sigma–Aldrich) (di-
luted 1:2000 in blocking solution) for 1 h at room temperature. Detection of immunocomplexes took place using the
ECL method, exposing X-ray film (Fuji) at different time points (30 s to 1 min) following by developing. Molecular
weight approximations are taken by comparing the stained bands to that of the marker proteins.
Orexin-mediated signalling in cardiomyocytes
Following the isolation of calcium tolerant cardiomyocytes (n=6), the cells were treated in a concentration (0.01–100
nM) and time (0–60 min) dependent manner with both OR-A and OR-B. Following these optimisation experiments,
orexin-induced phosphorylation of various signalling cascades, i.e. Akt, extracellular signal-regulated kinase (ERK)
1/2 (ERK1/2), Troponin-I (TnI), and Myosin Light Chain were determined by Western blot analyses, as described
previously [24].
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Measurement of cell contraction and intracellular calcium
Contraction and intracellular calcium [Ca2+]i were determined in isolated ventricular cardiomyocytes (n=6), as pre-
viously described [21]. Cells were classified as either contractile or non-contractile in response to electrical stim-
ulation. To measure [Ca2+]i, myocytes were loaded with fura-2 and excited alternately at 340 and 380 nm with a
monochromator and emitted light collected at >520 nm and measured using a photomultiplier tube (Photon Tech-
nology International). Contraction strength is shown as percentage cell shortening and [Ca2+]i as Fura2 ratio.
Determination of infarction following ischaemia/reperfusion in the
isolated Langendorff perfused rat heart
All experiments lasted for 195min.Hearts were allowed to stabilise for 30minwith the standardTyrode’s solution per-
fusion. Contractile parameters from the data files were calculated by averaging aminimumof six cycles per data point
to obtain themean value for left ventricular systolic pressure (LVSPmmHg), and left ventricular end diastolic pressure
(LVEDPmmHg) (measured at t0, t30, t40, t75, t85, t100, t130, t160 and t195 min). The difference between these two
pressure values represented the left ventricular developed pressure (LVDP,mmHg). Heart rate (HR, beats.min−1) was
determined at the same time points together with the rate pressure product (RPP, mmHg), which was calculated by
multiplying the LVDP and HR (average value of LVDP is obtained from averaging both systolic and diastolic values,
then the mean is multiplied by HR to obtain RPP).
Global ischaemia was produced for 30 min by stopping flow of physiological solution to the heart. At the end of
reperfusion, the heart was frozen at −20◦C before being sliced into 2 mm thick transverse sections and stained with
2% TTC, which reacts with intracellular dehydrogenases present in viable cells producing a red pigment and staining
viable tissue red (whereas infarcted tissue remains pale) and then fixed in 10% formalin overnight to enhance the
contrast. Each section was then photographed with a digital camera and then traced on to a clear acetate sheet to
determine infarct size (% infarct area = infarct area on each slice/total area of the heart slice × 100) [25]; the area
was calculated using computer-assisted planimetry [NIH image 1.57] [26–28].
For the inhibitor studies, the rats were randomly assigned to one of the following groups: (i) control group, where
they were subjected to 30 min of global ischaemia followed by 120 min of reperfusion, and the treated heart groups,
which received inhibitor (wortmannin; 1μmol/l orU0126; 10μmol/l) togetherwithOR-Bperfusionwhichwas added
to Tyrode’s buffer after stabilisation and perfused for 10 min prior to 30-min global ischaemia and switched back to
normal Tyrode’s during 120 min reperfusion. In addition, some hearts only received the inhibitors (wortmannin or
U0126) to rule out any influence they may have directly upon infarct size.
Inducing ischaemia in rats in vivo
Rats were anaesthetised with 3% isoflurane inhalation and then intubated via a tracheostomy and ventilated with a
mixture of O2 and 1.5–3% isoflurane, using a rodent ventilator. A left thoracotomywas performed through the fourth
intercostal space, pericardium opened and the left coronary artery (LCA) located and ligated with a 4-0 silk suture.
The ligation was confirmed successfully when the anterior wall of the LV turned pale around the area that was tied off
using a snare. Following 30 min of regional ischaemia, the snare was released and blood allowed to flow freely during
120 min of reperfusion. At the end of the experimental protocol, the hearts were removed and perfused on to the
Langendorff system for staining. The ligation was tied off and hearts perfused with 1% Evans Blue to demarcate the
area at risk (AAR), followed by TTC staining to identify the viable tissue staining deep red. The infarct area within the
risk area was then calculated (I/R %). The same surgical procedure was followed for sham group without occlusion
of the LCA (data not shown).
Determination of infarction following ischaemia/reperfusion in the in vivo
rat heart
At the end of reperfusion, the rat was overdosed with pentobarbital and the heart was rapidly removed and mounted
on to the Langendorff apparatus as above. The left anterior descending artery was ligated, 1 ml of 0.25% Evans Blue
(in PBS) was then injected into the heart and allowed to perfuse followed by normal Tyrode’s for a further 2 min to
delineate the area not at risk (ANAR) staining it blue [29]. The heart was stored at−20◦C before being sectioned into
2-mm sections and stained with TTC to determine the infarct size as stated above. The percentage infarct tissue (I)
within the AAR was calculated as I/AAR %. Furthermore, the ischaemic area (AAR) was distinguished from ANAR.
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Table 1 Selected key patient characteristics prior to cardiac surgery and tissue collection for the heart failure study
patients, including age, gender, hypertension, hyperlipidaemia, type 2 diabetes mellitus, smoking status and body mass
index
Participants (n) 54
Age (years) 65.2 +− 1.3
Male gender (%) 50 (92.6)
Hypertension (%) 30 (55.6)
Hyperlipidaemia (%) 31 (57.4)
Type 2 diabetes mellitus (%) 16 (29.6)
Smoking - active (%) 26 (48.1)
- ex (%) 13 (24.1)
BMI (kg/m2) 27.29 +− 0.50
Data are presented as mean +− S.E.M. or as frequencies. Abbreviation: BMI, body mass index.
Orexin in the human heart
The clinical study was approved by the Research Ethics Committee South-Central Oxford C (11/SC/0140). All par-
ticipants provided written informed consent, in accordance with the Declaration of Helsinki.
Orexin gene expression in human myocardial tissue
To explore whether our findings from the cell cultures and animal model could be of relevance to CVD in humans,
we investigated OX2R gene expression levels in human myocardium samples. A cohort of 54 patients undergoing
coronary artery bypass grafting with available myocardial cDNA library was used for this purpose (Table 1); relative
expression was calculated using the Pfaffl method, with phosphoglycerate kinase 1 (PGK1) as housekeeping gene
[30].
Orexin signalling in the human myocardium
To examine the direct effects of OR-A and OR-B on intracellular signalling in the human heart, human myocardial
tissue samples were collected from the right atrial appendage of eight patients undergoing cardiac surgery. These
myocardial tissue samples were washed in ice-cold Krebs HEPES buffer and then cut into thin strips containing all
myocardial layers. The tissue was first equilibrated for 10 min in Krebs HEPES buffer at 37◦C and then incubated
for 20 min in the presence or absence of human recombinant OR-A (100 nM) or OR-B (100 nM) (Phoenix Pharma-
ceuticals Inc., Burlingame, CA, U.S.A.). At the end of the experiment, incubated tissue samples were collected and
stored at −80◦C until assayed. Western immunoblotting was used to examine the direct effects of OR-A and OR-B
on p-Akt (Ser473), total-Akt, (Cell Signaling, Danvers, MA), and phospho/total ERK1/2 (Abcam, Cambridge, Eng-
land, United Kingdom) in human myocardial tissue. Briefly, myocardial tissue samples were homogenised for 30 s
using a pre-cooled electric Polytron homogenizer in 220 μl of lysis buffer (Invitrogen, U.K.) containing a protease
plus phosphatase inhibitor cocktail (Roche Applied Science). Homogenates were spun at 13000 rpm for 10 min at
4◦C. The protein concentration of the supernatants was then measured using the BCATM Protein Assay kit (Pierce,
U.K.). Protein lysates were separated on 12% gradient SDS-NuPAGE gel (Invitrogen, U.K.), and proteins transferred
to PVDFmembranes (AmershamUK Ltd.), followed by blocking with 5% powdered skimmedmilk. Themembranes
were incubated with the respective primary antibodies overnight and immunodetection of the primary antibodies
was performed with horseradish-peroxidase–conjugated secondary antibodies (Promega), and enhanced chemiflu-
orescence (Amersham Bioscience UK Ltd.), and quantified in relation to the house-keeping protein GAPDH (Santa
Cruz Biotechnology, Santa Cruz, CA).
Statistical analysis
All results are expressed asmean+− S.E.M., unless indicated otherwise. ForWestern blotting experiments, the densities
of the immunoreactive bands were measured using a scanning densitometer coupled to scanning software (Image-
Quant; Molecular Dynamics, Amersham Pharmacia, U.K.). Data were evaluated as in the study by Maulik et al. [31].
Statistical analyses among the Langendorff model perfused groups were performed using one-way ANOVA followed
by Bonferroni’s post hoc test with significance determined at the level of P<0.05.
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Results
Detection of cardiac prepro-orexin and OXRs
Using qRT-PCR, we demonstrate that both OXRs are expressed in the rat heart. Using rat hypothalamus as a positive
control, the expression of OX1R was significantly less in the heart (P<0.001), whereas OX2R expression levels were
similar between the heart and the hypothalamus (Figure 1A). Both OXRs were uniformly expressed throughout the
rat heart including the LV, left auricle (also known as left atrial appendage), interventricular septum, right ventricle
(RV) and right auricle (Figure 1D). Single-cell PCR from cardiomyocytes revealed expression of both OXRs in single
cells investigated (Figure 1E).
Using Western blotting, we also confirmed the expression of OXRs at the protein level in total rat heart and car-
diomyocyte cell lysates (data not shown). Immunohistochemical analysis of ventricular sections using specific anti-
bodies forOX1R (Figure 1B(I)) andOX2R (Figure 1B(II)) revealed awidespread cytoplasmic andmembrane distribu-
tion of bothOXRs across the rat ventricle. Cellular distribution ofOXRswas further investigated in rat cardiomyocytes
in vitro. Immunofluorescence revealed a similar distribution of OX1R (Figure 1C(I)) andOX2R (Figure 1C(II)). This
is consistent with the expression of GPCRs in the cytoplasm (due to trafficking or internalisation), as well as on the
cell membrane [32]. We then proceeded to study the expression of OXRs in the human heart using a cardiovascular
MTC panel demonstrating expression of both OXRs in multiple human cardiac compartments (Figure 1F).
We also demonstrated that prepro-orexin is expressed as a 302-bp PCR product in the LV, LA, interventricular
septum, RV and right atrium (RA) of the rat heart (Figure 1G). We have used Western blotting to demonstrate that
the prepropeptide can be cleaved into full-length OR-A (Figure 1H) and OR-B (Figure 1I), with molecular weights of
approximately 3.5 and 2.9 kDa, respectively. We then assessed the protein expression using immunohistochemistry.
Antibodieswere validated using rat thymus as a negative control and rat spleen and rat testes as positive control (Figure
1J and Supplementary Figure S2). Subsequent immunohistochemical analysis of rat ventricular sections revealed
protein expression of both cleaved peptides across the ventricle (Figure 1K and Supplementary Figure S2). Similar
expression was evident in individual cardiomyocytes (Figure 1L).
Cardiomyocyte contractility and calcium measurements
Superfusion of cardiomyocytes with Tyrode’s solution containing 10 nM OR-B increased the shortening of twitch
contraction (Figure 2A), from 15.2+− 1.2 to 20.6+− 1.7% (n=6, P<0.01; Figure 2B). This was not associated with any
change on either the amplitude (Figure 2A) or the rate of the Ca2+ transient decline (n=6, P=NS (no supplement);
Figure 2C). OR-A had no effect on the rat cardiomyocyte cell length even with concentrations as high as 100 μM
(data not shown; P=0.07). The OR-B effect was replicated using the specific OX2R agonist ([Ala11, d-Leu15]-OR-B)
(Figure 2D), while it was not blocked by an OX1R-specific antagonist (SB-408124) (Figure 2E), suggesting that these
effects are predominantly mediated via an OR-B/OX2R pathway.
Furthermore, OR-B, but not OR-A (data not shown), significantly induced phosphorylation of TnI at Ser23/Ser24
in cardiomyocytes. This effect was dose-dependent, with a maximum activation at 100 nM of OR-B (P<0.001; Figure
2F). Similarly, OR-B, but not OR-A (data not shown), induced significant phosphorylation of the myosin light chain
(MLC) at Ser19 with maximal effects at 100 nM and 15 min (P<0.001; Figure 2G).
OR-B exerts a cardioprotective effect
In both the isolated rat heart and the in vivo rat model, we measured LVDP, LV pressure decay and HR. The RPP was
then calculated; this was used as a clear and direct indication of the energy demand of the heart and, thus, a good
measure of the energy consumption of the heart pre- and post-ischaemia.
Initially, pre-treatment with either OR-A, OR-B or OX2R agonist, prior to the ischaemic insult, did not alter the
haemodynamic parameters orHR between any of the groups (data not shown). Contractile parameters were recorded
at various time points throughout the experimental protocol (Supplementary Figure S1). Following 30 min of global
ischaemia in the isolated Langendorff perfused rat heart model, the expected decline in cardiac function during
reperfusion, as observed in the control hearts, was not affected by pre-treatment with OR-A (Figure 3A). In contrast,
the pre- and post-treatment groups for both OR-B and the OX2R agonist resulted in significantly improved recov-
ery compared with control during reperfusion (P<0.05; Figure 3A,B). This was further replicated in the in vivo rat
model where the control group (saline treated) demonstrated poor cardiac functional recovery and cardiac function
following 30min of regional ischaemia and 120min reperfusion, whereas theOR-B pre-treated group [bolus injection
(i.v.) of OR-B (100 nM) 10 min prior to regional ischaemia] showed significant improvement in functional recovery
during reperfusion (P<0.05; Figure 3C). Concentration-dependent effects were noted with OR-B (20–100 nM), with
a maximal response at 100 nM (data not shown).
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Figure 1. Expression of orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the rat and human heart
(A) Quantificative RT-PCR analysis of OX1R and OX2R in the rat hypothalamus (hypo) and rat heart (***P<0.001 for heart compared
with hypothalamus). (B) Immunohistochemical analysis of rat heart ventricular sections (n=3) for OX1R (I) and OX2R (II). Magni-
fication ×400. Negative control (III) confirmed the specificity of the immunostaining. (C) Immunohistochemical analysis of OX1R
(I) and OXR2 (II) in rat cardiomyocytes and negative control (III). Identical results obtained from four independent experiments;
measuring at least 50 cells. (D) Expression of OX1R and OX2R in rat heart compartments (n=3). Lane 1 cDNA from LV; Lane 2
cDNA from left auricle; Lane 3 cDNA from septum; Lane 4 cDNA from RV; Lane 5 cDNA from right auricle; and Lane 6 is DNA
marker. (E) Single-cell RT-PCR in cardiomyocytes (n=6): Lane-1: β-Actin; Lane-2: OX1R; Lane-3: negative control; Lane-4: OX2R.
(F) Expression of OX1R and OX2R in different human cardiac compartments: Lane-1: aorta; Lane-2: apex of the heart; Lane-3: LA;
Lane-4: right atrium (RA); Lane-5: right auricle; Lane-6: left auricle; Lane-7: LV; Lane-8: RV; Lane-9: interventricular septum; and
Lane-10: atrioventricular (AV) node. (G) Expression of prepro-orexin in rat heart chambers (n=3). Prepro-orexin is expressed as a
302-bp PCR product in the LV (lane 1), LA (lane 2), interventricular septum (lane 3), RV (lane 4), and RA (lane 5). M = Marker; DNA
ladder. (H,I) Prepro-orexin (PPO) and the cleaved peptides OR-A and OR-B were detected using Western blotting, with molecular
weights of 15 kDa for PPO, 3.5 and 2.9 kDa for OR-A (H) and OR-B (I), respectively; Lane 1: rat heart lysates; and Lane 2: rat
hypothalamus lysates (n=3). (J) Immunohistochemical analysis for OR-A on rat thymus section (I) and rat spleen (II). (K) Immuno-
histochemical analysis of rat heart ventricular sections (n=3) for OR-A (I) and OR-B (II) and negative control (III). Magnification ×400.
(L) Rat cardiomyocyte immunofluorescent analysis of OR-A (I), OR-B (II) and negative control (III). Identical results obtained from
four independent experiments, measuring at least 50 cells.
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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Figure 2. Effects of OR-B on contractility of rat cardiomyocytes and on the phosphorylation of TnI and myosin light chain
Using video-edge detection system, changes in cell length of individual cardiomyocytes (n=6) were recorded upon challenge with
orexins. (A,B) Superfusion of the myocyte with OR-B (10 nM) increased the strength of twitch contraction (**P<0.01). (A,C) No
effect on the amplitude of the Ca2+ transient was observed. (D) Similar effects on the strength of twitch contraction was observed
following treatment with a specific OX2R agonist (OX2Ra: [Ala11, D-Leu15]-Orexin B) (*P<0.05). (E) Addition of an OX1R-specific
antagonist (OX1R Ant.: SB-408124) did not alter the OR-B cardiomyocyte contractile response (*P<0.05). (F) OR-B was able to
induce phosphorylation of TnI in a concentration-dependent manner (**P<0.01, ***P<0.001). (G) OR-B was able to induce phos-
phorylation of MLC in a concentration-dependent manner (**P<0.01, ***P<0.001). For the above experiments, equal protein loading
was confirmed, using β-actin as an internal control. B = basal (no OR-B). Abbreviation: MLC, myosin light chain.
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Figure 3. Cardiac functional parameters and infarct size determination following ischaemia (n=8)
(A–C) Panels depict the effects on left RPP = HR × LVDP, following 30 min of ischaemia (45–75 min) for: (A) Control (Con); pre-treat-
ment: OR-A, OR-B or OX2R agonist (OX2Ra) in the in situ rat model (ex vivo; isolated Langendorff model) (*P<0.05, compared with
control). (B) Control, post-treatment OR-B or OX2Ra in the in situ rat model (*P<0.05, compared with control). (C) Control, bolus
pre-treatment OR-A, OR-B, OX2Ra in the in vivo rat model (*P<0.05, compared with control). (D–F) Depict the effects on the LV
infarct size (% LV; transverse sections of the rat heart were obtained at the end of the experimental protocol and the sections were
stained using TTC so that the infarcted tissue appears pale, while viable tissue stains red). More specifically (D) Control; pre-treat-
ment with OR-A, OR-B and OX2Ra in the ex vivomodel (***P<0.001, compared with control). (E) Control; post-treatment with OR-B
or OX2Ra in the ex vivo model (***P<0.001, compared with control). (F) In vivo model with bolus pre-treatment with OR-A, OR-B
and OX2Ra prior to regional ischaemia and reperfusion (***P<0.001, compared with control).
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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Effects of OR-B reducing the LV infarct size
In isolated rat heart model pre-treated with OR-B for 10min prior to global ischaemia and reperfusion, the LV infarct
size was reduced from 61.5 +− 3.0% in the control to 22.6 +− 1.9% in the treated group (P<0.001; Figure 3D). In ad-
dition, the OR-B post-ischaemic treatment was just as effective at providing myocardial protection as pre-treatment,
since it also significantly reduced the LV infarct size to 21.8 +− 3.9% (P<0.001; Figure 3E). The OX2R-specific ag-
onist exhibited a similar protective effect to OR-B treatment, inducing a reduction in LV infarct size both during
pre-treatment (25.7 +− 3.6%) and at the start of reperfusion (34.7 +− 3.1%, both P-values<0.001 compared with con-
trol; Figure 3D,E). However, pre-treatment with OR-A alone showed no significant reduction compared with control
(58.3 +− 3.0 compared with 61.5 +− 3.0%, respectively; P=NS) in the LV infarct size (Figure 3D). Moreover, in the
in vivo model pre-treatment with a bolus injection (i.v.) of OR-B (and of ORX2Ra, but not of OR-A) 10 min prior
to regional ischaemia and reperfusion significantly reduced the %LV infarct size compared with the control (saline)
group (66.7+− 3.0 compared with 26.8+− 14.9% in the control and OR-B treated group, respectively; P<0.001; Figure
3F).
Involvement of distinct signalling pathways in myocardial protection
The isolated rat heart model was pre-treated either with an OX1R-specific antagonist or a PI3 kinase (PI3K) in-
hibitor (wortmannin) in the presence or absence of OR-B prior to ischaemia/reperfusion. Pre-treatment with either
the OX1R-specific antagonist or wortmannin alone showed no change in functional recovery compared with the con-
trol group (Figure 4A) and no effect on the %LV infarct size (61.5+− 3.0% in the control group compared with 61.8+−
1.9% with OX1R antagonist alone, and 56.5 +− 1.5% with wortmannin alone; P=NS, Figure 4B). Pre-treatment with
OR-B together with wortmannin showed no myocardial protection on cardiac functional recovery (P=NS; Figure
4A); and, abolished the OR-B protective effect on LV infarct size (P=NS, Figure 4B), suggesting the importance of
the PI3K/Akt pathway in OR-B induced cardioprotection. Improved functional recovery with OR-B pre-treatment
was not inhibited by the simultaneous administration of an OX1R-specific antagonist (P<0.05; Figure 4A). Similarly,
the OR-B protective effect on %LV infarct size was not blocked by the OX1R-specific antagonist (P<0.001; Figure
4B). Both these findings suggest that the noted effect is OX2R specific.
Given that ischaemic preconditioning protects the heart by phosphorylating the pro-survival kinases Akt and
ERK1/2 at reperfusion, we investigated further whether orexins can affect their phosphorylation [33]. Treatment with
OR-B increased the phosphorylation of both Akt and ERK1/2 compared with basal levels (P-values <0.001; Figure
4C–E); in contrast with OR-A which had no significant effect on ERK1/2 (Figure 4E) and Akt (data not shown). The
OR-B effect was concentration dependent (Figure 4D). The time course for the ERK1/2 activation was for 3, 5, 10
and 15 min. The involvement of an MAPK pathway was further corroborated using the selective MAPK inhibitor
U0126, demonstrating that inhibition of the MAPK pathway using U0126 abrogates the protective effect of OR-B on
LV infarct size (Figure 4F).
OX2R expression in patients with heart failure, and involvement of the
ERK1/2 pathway
To further evaluate the potential implication of orexins and their receptors in cardiac disease in humans, we studied
OXR downstream signalling and expression in cardiac tissue samples from adult patients undergoing cardiac surgery
and coronary artery bypass grafting. In the context of these studies, all human myocardial tissue samples were col-
lected from the right atrial appendage during cardiac surgery.
Using Western blotting, we examined the direct effects of OR-A and OR-B on the phosphorylation of Akt and
ERK1/2 in heart tissue samples from eight patients. Treatment with OR-A or OR-B did not change Akt phospho-
rylation compared with basal levels (Figure 5A), while only OR-B significantly increased ERK1/2 phosphorylation
compared with control (non-treated heart tissue; P<0.05; Figure 5B).
In addition, we measured OXR expression levels in heart tissue samples from heart failure patients undergoing
coronary artery bypass grafting (n=54; Table 1). Our results demonstrated a negative correlation between the sever-
ity of heart failure symptoms and the expression ofOX2R.As such, when patients were categorised using theNewYork
Heart Association (NYHA) functional classification of heart failure (classes I–IV based on increasing severity of clin-
ical symptoms) there was a significant decrease in OX2R in NYHA-II compared with NYHA-I and in NYHA-III/IV
compared with NYHA-II and NYHA-I (P-values<0.05; Figure 5C).
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Figure 4. OR-B/ OX2R effects on key signalling pathways involved in myocardial protection using the isolated Langendorff
perfused rat heart model (n=8)
(A) Cardiac functional performance measured and represented as left RPP in rat hearts pre-treated with control (saline treated),
OR-B plus OX1R antagonist, OX1R antagonist alone, OR-B plus wortmannin (wort; a PI3K inhibitor) and wortmannin alone (*P<0.05
compared with control). (B) LV infarct size determination (%LV) in pre-treated hearts with OR-B plus OX1R antagonist, OX1R
antagonist alone, OR-B plus wortmannin and wortmannin alone (***P<0.001 compared with control). Dotted line across denotes
control levels. (C) OR-B time-dependent treatment and Akt phosphorylation: exposure of rat cardiomyocytes to OR-B (100 nM)
induced maximal phosphorylation at 5 min. Change in the phosphorylation was evident as early as 2 min post-treatment (*P<0.05,
***P<0.001 compared with basal). (D) OR-B induced a dose-dependent induction in the phosphorylation status of Akt, becoming
significant at 1 nM and reaching a plateau at 100 nM (**P<0.01, ***P<0.001 compared with basal). (E) OR-B treatment increased
the phosphorylation of ERK1/2 compared with basal levels (***P<0.001). Isoproterenol (ISO) and Angiotensin-II (Angio-II) were
employed as positive controls. (F) Inhibition of theMAPK pathway using a selectiveMAPK inhibitor (U0126) abrogates the protective
effect of OR-B on LV infarct size (*P<0.05, **P<0.01, ***P<0.001 compared with control; aP<0.05 compared with OR-B).
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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Figure 5. Orexin-induced signalling and orexin receptor expression in heart samples from cardiac surgery patients
(A,B) In human heart tissue obtained from patients undergoing coronary artery bypass (n=8), both OR-A and OR-B showed no
change in Akt phosphorylation compared with the non-treated heart tissue (100 nM). Change in the phosphorylation state was
evident for ERK1/2 signalilng in the OR-B treatment group (*P<0.05 compared with control). (C) Expression of OX2R in heart
samples from heart failure patients (n=54) demonstrated a significant decrease in OX2R in NYHA-II compared with NYHA-I patients
(ǂP<0.05) and in NYHA-III/IV compared with NYHA-II (*P<0.05) and to NYHA-I patients (†P<0.05) and NYHA-III/IV compared with
NYHA-I (aP<0.05). NYHA: New York Heart Association Functional Classification for heart failure stages.
Discussion
In the present study, we have shown that the heart constitutes a source of orexins and expresses functional OXRs.
Moreover, our experiments revealed that OR-B can exert direct cardioprotective effects in both ex vivo and in vivo
rat heart models.
Indeed, using the Langendorff perfused rat heart model, pre- and post-myocardial ischaemia treatments with both
OR-B and a selective OX2R agonist resulted in significantly increased RPP which is a direct indication of the energy
demand of the heart and, thus, a good measure of the energy consumption of the heart pre- and post-ischaemia.
In the case of the ex vivo studies that replicate the in vivo results, additional interactions between sympathetic
activity, which is increased in ischaemia [34], and OXR signalling through cAMP [35] cannot be ruled out. Addi-
tionally, treatment of ventricular cardiomyocytes with OR-B, but not OR-A, lead to significantly increased Tn-I and
MLC phosphorylation, followed by a concomitant increase in the strength of their twitch contraction. Of note, these
findings agree with previous studies demonstrating that changes in the phosphorylation of key cardiac regulatory
proteins can affect cardiac function [36,37].
This is the first observation of a differential specificity of OR-A and OR-B in the heart. OR-A activates both OX1R
and OX2R receptors with similar potencies (∼36 nM), whereas OR-B selectively activates OX2R compared with
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OX1R (∼420 nM) [38]. Both receptors belong to the GPCR superfamily and are highly promiscuous in terms of
their G-protein coupling characteristics [39]. These tend to be cell- and tissue-specific and influence subsequent
activation of downstream signalling pathways. For example, we have previously shown that expression of human
OX2R is regulated by a complex involving a proximal PKA/PKC-regulated promoter and a distal promoter regulating
tissue-specific expression of alternative transcripts which in turn post-transcriptionally regulate receptor levels [40].
Therefore, future studies are required to provide further insight into the regulation of the promoter of OX2R in the
myocardium.
Moreover, a dichotomous role of OXRs is evident in the rat brain, where OX1Rsmediate the neurobiological effects
that drive drug seeking, whereas OX2Rs play a crucial role in sleep/wake cycle regulation and arousal [41]. Interest-
ingly, OR-A, but not OR-B, can activate electrophysiologically the subfornical organ of rat neurons [42]. In a more
recent study, OR-A (100 nM) and OR-B (100 nM) increased leptin gene expression in differentiated preadipocytes
by 49.9 and 71.3% respectively [43], indicative of differential modulation of transcriptional responses by these two
peptides.
This phenomenon has been previously described for other GPCRs. In the case of smooth muscle cell
CRH-receptors, urocortin, but not CRH, activated the MAPK signal transduction pathway despite similar binding
affinities [44]. Thus, it is possible that differences on OR-A and OR-B responses could also be influenced by the car-
diacmicroenvironment, leading to alternative coupling of G proteins and activation of distinct signalling pathways. In
previous studies, we have shown that OX2Rs can differentially couple to Gq, Gi/o and Gs proteins in different tissues
[19,22,39]. Emerging studies have also shown that OXRs can form functional dimers. It is possible that dimerisation
can also take place at the cardiac level and therefore influence pharmacological properties, such as the affinity of the
receptors for orexin ligands, as well as cellular distribution and trafficking [45]. Finally, polymorphisms of theOX2R
gene have also been described previously [46]. To this date, dimerisation or polymorphisms have not been explored
in the myocardium. Future studies should determine whether dimerisation or polymorphisms of cardiac OXRs may
affect ligand binding, or indirectly affect ligand binding by altering receptor structure.
In the present study, using an OX1R antagonist and an OX2R agonist, we conclude that the primary signalling at
the rat heart is mediated via an OR-B/OX2R pathway. OXRs are able to activate certain key plasticity-regulating cas-
cades, such as PI3K and ERK, and p38 MAPK. Here, pre-treatment with wortmannin abolished the OR-B protective
effect on LV infarct size; suggesting the involvement of the PI3K/Akt pathway in OR-B induced cardioprotection.
This signalling pathway has been implicated in myocardial protection; and is referred to as the reperfusion injury
signalling kinase (RISK) pathway [33]. Mediators that target the activation of the RISK (PI3K/Akt) pathway have
been also shown to ameliorate recovery following ischaemic stress [25,47]. In our study, OR-B, but not OR-A, was
able to induce the phosphorylation status of both Akt and ERK1/2. Our data contradict previous studies showing that
both orexin peptides can increase Akt phosphorylation. For example, in a study of neuronal cell cultures OR-B was
more potent than OR-A, but the maximal effect of both peptides on the Akt activation was very similar [48]. This ap-
parent contradiction could be attributed to the fundamental differences between cardiomyocytes and neuronal cells
including morphological polarity, shape and function of action potentials, synaptic and homoeostatic plasticity; not
to mention the spatial expression of OXRs in the brain [49]. As such, it is plausible that orexins exert their effect in
an organ- and cell-specific manner.
The OR-B selectivity in post-translational modification of key mediators is corroborated by previous studies in
other tissues. Indeed, in the human testis, when IP3 turnover was measured, OR-B exerted a more potent effect
compared with OR-A [18]. Similarly, in human H295R adrenocortical cells’ diverse roles have been noted for OR-A
and OR-B in terms of activation of MAPKs and cortisol release; i.e. only OR-A (at 1 nM) activated ERK1/2 and p38
[50].
Based on our findings, herein we propose the presence of a signalling pathway involving OX2R-ERK1/2-MLC
in the heart with a net effect of increased Ca2+ sensitivity and cell length/contractility following OR-B superfusion
in cardiomyocytes [21,51–54]. Activation of ERK1/2 is involved in the activation of contractile responses through
mechanisms involving direct phosphorylation of the Ca2+/calmodulin-dependent MLC kinase (MLCK) [33,55–57].
In a seminal review by Spinazzi et al. [58] , a case is made for mediation of Ca2+ by OXRs. However, this effect of
OX1R and OX2R on Ca2+-release is through IP3 receptor activation, which, although evident in the hypothalamus,
does not impact on the contraction of rat ventricular cardiac muscle under basal conditions, where the ryanodine re-
ceptors (RyR) dominate excitation–contraction (E–C) coupling [59]. As such, this may have more of a role in patho-
physiology of heart failure and arrhythmias [60]. Interestingly, the dominant expression of IP3 receptors is on the
nuclear membrane where they are thought to be involved in cardiac hypertrophy [61].
Conversely, inhibition of ERK attenuates force development by lowering MLC phosphorylation in cardiac tissue
[62]. Because of its central role in the regulation of contraction and relaxation of the heart, cardiac TnI (cTnI) is
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also phosphorylated by OR-B to ensure appropriate function. Changes in the phosphorylation status of cTnI are well
documented during acute cardiac events and in patients with heart failure [63].
We have expanded on these observations using human heart tissue samples from heart failure patients. So far, a
number of studies indicated that there is a dysregulation of the orexin system in the CNS in models of heart failure
[64–66]. Here we further report that in adults with heart failure (NYHA classes I–IV) there was a significant nega-
tive correlation between the severity of clinical symptoms (NYHA class) and OX2R expression. The fact that OX2R
expression was significantly lower in patients with NYHA classes III/IV compared with less symptomatic patients
with NYHA class I/II, indicates that OX2R signalling is compromised in more severe heart failure. These observa-
tions are further supported by the findings of Perez et al. [67], where in a heart failure model, hypocretin receptor
2 (HCRTR2)/OX2R-deficient mice exhibited poorer cardiac function, and greater myocardial scarring. Moreover,
in the same study, differential OX2R expression data from microarray experiments were recorded in patients with
dilated cardiomyopathy and ischaemic cardiomyopathy [67].
Based on the established role that orexins have in maintaining the awake state, orexin antagonism has also been
identified as a novel therapeutic approach for the treatment of insomnia [68]. As such, suvorexant, a non-selective dual
orexin (OX1R/OX2R) receptor antagonist (DORA), has been approved by the FDA, in 2014, for treating insomnia
patients with difficulties in sleep onset and/or sleep maintenance (http://www.acc.org/latest-in-cardiology/articles/
2015/06/16/08/40/new-insomnia-drugs-in-the-context-of-cardiovascular-disease - BELSOMRA R© (suvorexant)
package insert: http://www.merck.com/product/usa/pi circulars/b/belsomra/belsomra pi.pdf). To date, suvorexant
use has not been associated with any reported adverse cardiovascular safety outcomes; however, it must be high-
lighted that it is unknown whether suvorexant has adverse effects in CVD patients, since patients with signif-
icant and/or recent CVD (e.g. with acute coronary syndrome or congestive heart failure) were excluded from
the relevant trials (http://www.acc.org/latest-in-cardiology/articles/2015/06/16/08/40/new-insomnia-drugs-in-the-
context-of-cardiovascular-disease). Therefore, and based on the findings fromour study and fromothers [67], the use
of orexin antagonists may warrant further assessment and careful monitoring for CVD adverse effects, particularly
in heart failure patients [69].
Finally, our human ex vivo study results were also consistent with the in vitro rat data, since orexin treatment
of human myocardial tissue demonstrated that OR-B, but not OR-A, was able to induce ERK1/2 phosphorylation.
However, there was no change in Akt phosphorylation upon treatment with OR-A or OR-B. The latter could be due
to the fact that chronic heart failure reduces Akt phosphorylation, so signalling is already compromised at basal lev-
els. Indeed, compared with subjects with normal cardiac function, human skeletal muscle of heart failure patients
demonstrates reduced Akt phosphorylation [70]. It should be noted that the cardiovascular and musculoskeletal sys-
tem are interrelated, whereby a functional deterioration in one is reflected similarly in the other [71]. Differences in
the phosphorylation of Akt can also be due to species differences, since certain proteins, like ETS-related gene (ERG),
are differentially expressed in the rat and human heart [72].
We also acknowledge certain limitations with our experimental system using healthy young adult rats compared
with patients used in the present study that have certain comorbidities. To date, it has proven difficult to find the ‘per-
fect’ translational in vivomodel for CVD. This is primarily due to the high level of complexity, as well as heterogeneity
of these diseases, in addition to potential impact/influence from environmental or genetic factors. Future studies can
make use of different animal models for examples such as; heart failure, aged rats or rats fed on a high-fat diet to
generate further data on the involvement of OR-B/OX2R at the cardiac level. However, to the best of our knowledge,
there is no perfect in vivo model to represent the entire repertoire of defects/comorbidities at the cardiac level.
In summary, our present findings document that OR-B exhibits a protective role on cardiac function pre- and
post-ischaemia, leading to reduction in the infarct size. We also provide novel conclusive evidence that the rat heart
expresses functional OXRs and is a source of orexins. Cardiac OXRs can also influence contractile tone via mech-
anisms involving phosphorylation of TnI and MLC. Thus, in addition to the known CNS effects of orexins/OX2R
[5,73], our data illustrate the importance of the OX2R as a potential therapeutic target directly at the heart level,
suggesting that targeted use of OX2R-specific agonists may have a role in the prevention and treatment of CVD.
Clinical perspectives
• Several cardiovascular drugs exert their cardiac actions via GPCRs, and orexins acting via their
GPCRs can affect the heart centrally. In the present study, we tested whether orexins and their
receptors can exert a direct effect at cardiac level.
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• The human and rat heart constitute a source of orexins and express functional OXRs. OR-B can
exert direct cardioprotective effects in both ex vivo and in vivo rat heart models. In adults with
heart failure there was a significant negative correlation between the severity of clinical symptoms
(NYHA class) and OX2R expression in the human heart.
• Based on the findings from our study, the use of orexin antagonists warrants further assessment
and careful monitoring for CVD adverse effects, particularly in heart failure patients.
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